News stories about Chimerix (NASDAQ:CMRX) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chimerix earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.7178655261441 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

CMRX has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Tuesday, July 17th. ValuEngine raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Chimerix in a research note on Thursday, June 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $7.08.

Shares of NASDAQ CMRX traded up $0.02 during mid-day trading on Friday, hitting $4.38. The company’s stock had a trading volume of 138,870 shares, compared to its average volume of 123,335. The firm has a market capitalization of $209.16 million, a PE ratio of -2.90 and a beta of 1.36. Chimerix has a one year low of $4.06 and a one year high of $5.94.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $0.94 million. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 33.76%. equities research analysts expect that Chimerix will post -1.79 EPS for the current year.

In other Chimerix news, insider M Michelle Berrey bought 10,000 shares of Chimerix stock in a transaction dated Tuesday, June 12th. The shares were bought at an average price of $4.50 per share, with a total value of $45,000.00. Following the purchase, the insider now owns 325,256 shares of the company’s stock, valued at $1,463,652. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ernest Mario sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $4.79, for a total transaction of $143,700.00. Following the completion of the transaction, the director now directly owns 12,905 shares in the company, valued at approximately $61,814.95. The disclosure for this sale can be found here. Insiders sold a total of 127,553 shares of company stock worth $603,546 in the last ninety days. Insiders own 12.50% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with's FREE daily email newsletter.